PFIZER, GSK, DR REDDY’S LABS & HETERO ARE THE JURY’S NOMINEES FOR INDIA LEADERSHIP CONCLAVE BUSINESS AWARDS 2011 IN PHARMACEUTICAL SEGMENT

With voting open in public, experts feel that the battle & competation is going to be a close one considering the robust performance of all these four player. 22nd April 2011 will decide who will receive the coveted Award . Voting Options : SMS* DR REDDY’S OR PFIZER OR GSK OR HETERO & SEND IT TO ++ 91 09892108169 : Email JET OR INDIGO OR FLY KINGFISHER OR SPICEJET OR INDIAN AIRLINES SEND TO nominations@indialeadershipconclave.com
Maharashtra, Mumbai: 14th Feb 2011 : Business Leadership Awards 2011 from Indian Affairs Magazine ( www.indianaffairs.in ) & Indo-American Chamber of Commerce is gaining momentum as all award categories. Nominations in various industry verticals has been announced a fortnight ago by the juries for voting. India Leaders Conclave’s Business Leadership Awards 2011 ( www.indialeadershipconclave.in ) aim to acknowledge & honour the remarkable achievemts by the companies & individuals who defied all odds & performed under an extreme situations after the jolt that prevailed in global economy slowdown. The pharmaceutical industry represents the largest sector of the life sciences sector in India, despite being highly fragmented with thousands of firms, distributors and retailers. Research and development activities have become more prevalent recently as the industry moves away from the core manufacturing of generic drugs. Traditionally, the Indian pharmaceutical industry has been characterized by a core competency in generics’ manufacturing and relatively immature capabilities in R&D. This outlook has evolved substantially since the 1990s and Indian companies have been making investments towards expanding drug discovery and development capabilities. The acceptance of patent laws and the rise of contract manufacturing have led to the diversification of revenue streams, enabling Indian pharma companies to experience high market growth.
The stage therefore is set for an intense competition as Mergers & Acquisitions will continue to be the order of the day. Foreign Direct Investment will also flow in as Indian market is perceived lucrative to the whole world. The Juries therefore shortlisted four Companies that have come into the centre stage due to their consistent performance & market dominance. PFIZER, GSK , DR REDDY’S LABS & HETERO (www.pharmaleaders.co.in )are the nominees for the high profile India Leadership Awards 2011 to be presented on April 2011 in a power-packed gatherings that will comprise who’s & who’s of Corporate world in business, politics, media, bollywood, social service. Dr Reddy’s share prices in last one month has been consistent with 10.74 per cent up on the Bombay Stock Exchange today riding at Rs 1522.00 per share. While Pfizer’s share price in last one month has been a rosy look with 7.06 percent up on the Bombay Stock Exchange & riding at 1215.00 per share. While GlaxoSmithKline Pharmaceuticals Ltd with 7.18 percent with 2240.00 per share.
Pfizer Limited (India) has a turnover of US$ 159.52 million (November 2009) One of the highest spenders in pharmaceutical R&D globally, Pfizer has made clinical research investments of US$ 6.05 million (November 2009) in India. Six of Pfizer brands feature among the Top 100 pharmaceutical brands in India. Two of Pfizer India’s brands Corex (Cough Formulation) and Becosules (Multivitamin) continue to rank among the Top 10 pharmaceutical drug brands. Pfizer has won the Golden Peacock Innovative Product for Magnex (Sulperazon). In India, GSK is one of the market leaders with a turnover of Rs. 2003 crore and a share of 5.0 percent . GSK leads in several therapeutic segments – dermatology, anti-helmentics, hormones. GSK has 7 products in the top 50 brands, and the top five GSK products are Augmentin, Calpol, Ceftum, Phexin, and Betnesol. GSK’s vaccines division is ranked first in a fast-growing vaccines market. Some leading products in India are Havrix, Varilrix,Rotarix,Hiberix and Cervarix . GSK India’s R&D centres at Thane and Nashik have been granted recognition by the Department of Scientific and Industrial Research, Government of India . The number of clinical studies conducted in India is rapidly growing across a range of therapy areas. Dr. Reddy’s Laboratories is an emerging global pharmaceutical company. As a fully integrated pharmaceutical company, it has Global Generics, which includes branded and unbranded generics; and Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated Formulations, and Generic Biopharmaceuticals. Dr. Reddy’s Laboratories reported consolidated net profit Rs. 273.14 crore in the quarter ended December 2010 as against net loss of Rs. 521.70 crore in corresponding previous quarter, thanks to expansion of Gross profit margins by 400 basis points to 54.9%. However, Operating profit margins remained flat at 14.4% on the back of rise in operating expenses due to one time litigation costs in US and higher selling and marketing costs linked to the seasonality in the branded markets of India, OTC portfolio related spend in Russia. Operating profit increased by 10% to Rs. 273.59 crore. Company’s revenues registered a growth of 10% to Rs. 1898.51 crore largely driven by growth across its key markets North America, India and inline with that moderate growth across all other geographies except Europe. The growth was powered by 16% rise in global generics (68% of total sales) to Rs. 1358.81 crore. Interestingly, it’s PSAI (Pharmaceutical Services and Active Ingredients) business has degrown by 2% to Rs. 584.94 crore based on segment results. Hetero Drugs, the unlisted pharma major run by Dr B P S Reddy has shown much resilence & has been ballistic in performance & has obviously outsmarted & outperformed all players & the group now is more than a 2000 Crore Group . In an interview to PharmaLeaders Magazine ( www.pharmaleaders.co.in ) Dr Reddy told that his aim is to be Billion $ Company in next two years.